Memolan

Memantine Hydrochloride, the active ingredient in Memolan, is an NMDA receptor antagonist presented as an oral tablet for oral administration. It is indicated for the symptomatic treatment of moderate to severe Alzheimer’s disease in adult patients, helping to improve cognition, function, and behavior by reducing excitotoxic neuronal damage.

GNH USA supplies Memolan as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide. The company adheres to stringent quality standards and provides regulatory documentation to support import and distribution.

Memolan (memantine hydrochloride) is used in the management of Alzheimer’s disease, a neurodegenerative disorder affecting cognition.

- Moderate to severe Alzheimer’s disease: provides symptomatic improvement in cognition, daily functioning, and behavioral symptoms. - Alzheimer’s disease (any stage) as adjunct therapy: may be added to other dementia medicines to enhance overall clinical response. - Behavioral disturbances in Alzheimer’s disease: can help reduce agitation and aggression associated with the condition.

Common Side Effects: - Dizziness: transient feeling of light‑headedness. - Headache: mild to moderate intensity. - Constipation: reduced bowel movements. - Confusion: occasional disorientation. - Somnolence: increased sleepiness. - Hypertension: elevated blood pressure readings.

Serious or Rare Side Effects: - Seizures: convulsive episodes requiring immediate medical attention. - Severe allergic reactions: rash, swelling, or anaphylaxis. - Hallucinations: visual or auditory disturbances. - Cardiac arrhythmia: irregular heart rhythm that may be life‑threatening.

Memolan should be used with caution in specific clinical situations.

- Renal impairment: assess kidney function and consider dose adjustment. - Hepatic impairment: monitor liver enzymes and adjust therapy as needed. - History of seizures: observe for increased seizure activity. - Concomitant NMDA agonists: avoid co‑administration to prevent antagonistic effects. - Elderly patients: monitor for confusion, falls, and worsening cognition. - Store at ambient temperature: keep below 25 °C in the original packaging, protect from moisture and direct sunlight.

Memolan may interact with several medicines; monitoring is advised.

Major Interactions (Avoid): - Amantadine: additive NMDA antagonism may increase toxicity. - Dextromethorphan: combined CNS effects can lead to excessive sedation. - Ketamine: overlapping NMDA blockade may exacerbate adverse reactions.

Moderate Interactions (Monitor Closely): - CNS depressants (e.g., benzodiazepines): may enhance sedation. - Antihypertensive agents: potential for additive blood pressure lowering. - Diuretics: monitor electrolytes and renal function when used together.